Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2008 by Rogers Center for Research & Training, Inc..
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Rogers Center for Research & Training, Inc.
Information provided by:
Rogers Center for Research & Training, Inc.
ClinicalTrials.gov Identifier:
NCT00743834
First received: August 28, 2008
Last updated: September 3, 2008
Last verified: September 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will test the hypotheses that: 1. 12 weeks of Luvox-CR plus web-based Cognitive-Behavioral Therapy (CBT) [CT-STEPS] will produce greater symptom relief of OCD than treatment with Luvox-CR alone; and, 2. subjects receiving 12 weeks of CT-STEPS added to Luvox-CR treatment after 12-weeks of Luvox-CR monotherapy will experience greater OCD symptom relief (from weeks 12-24) than those continuing Luvox-CR treatment and having access to CT-STEPS from week one. 3. subjects who begin CT-STEPS at week 12 will be more likely to complete it than those who begin CT-STEPS at baseline.
| Condition | Intervention | Phase |
|---|---|---|
|
Obsessive Compulsive Disorder |
Drug: Luvox CR Behavioral: Behavioral Therapy |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD |
Resource links provided by NLM:
Further study details as provided by Rogers Center for Research & Training, Inc.:
Primary Outcome Measures:
- The primary outcome measure (Y-BOCS score) will be obtained by clinician rating [ Time Frame: screening, baseline, and end of weeks 4, 8, 12, 16, 20 and 24. ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
A
Effectiveness of Luvox CR plus Web-based CBT for OCD
|
Drug: Luvox CR
In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
Behavioral: Behavioral Therapy
The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
|
Detailed Description:
Primary Endpoint(s): Change in Y-BOCS score from baseline to endpoint at weeks 12 and 24; and, number (and percent) "responders" at weeks 12 and 24, defined as subjects with a 35% decrease in Y-BOCS score at endpoint and a Clinical Global Impressions score of 1 or 2 (very much or much improved).
Secondary Endpoint(s):
- change in scores on the Work and Social Adjustment Scale, a quality of life measure
change in scores on the Work Productivity and Activity Impairment
Questionnaire:
Specific Health Problem scale; in particular, we will analyze change in work hours/week lost because of OCD, and change in effect of OCD on work productivity (0-10 scale).
- dollar cost per responder
- dollar cost per total number of patients needed to produce one additional responder in the Luvox-CR plus web-based CBT group over the number produced by Luvox-CR alone, i.e., dollar cost per number needed to treat
- dollar cost per 5% decrease in Y-BOCS score at weeks 12 and 24 in the two treatment groups.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Men and women aged 18 years, with OCD of at least 1 year's duration, meeting DSM-IV diagnostic criteria, and having a baseline Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of 18.
Exclusion Criteria:
- Pregnant or nursing women or women of childbearing age not using an effective contraceptive method
- Organic mental disorder
- Bipolar disorder
- Psychotic disorder
- History of substance abuse or dependence within 3 years of evaluation for study
- Major depression with suicidal risk
- Major depression dominating the clinical picture
- Panic disorder
- Personality disorder severe enough to interfere with cooperation with study procedures
- Need for antipsychotic medication
- Depot neuroleptic drug within 6 months
- Fluoxetine within 5 weeks
- An MAOI within 2 weeks, any nightly sedative, or taking a medication that may interact with fluvoxamine
- Serious or unstable medical condition (hematological, endocrine, cardiovascular, renal or gastrointestinal), a history of malignancy (other than excised basal cell carcinoma), history of brain disease, including more than one childhood febrile convulsion and all forms of epilepsy; or, are receiving behavior therapy for OCD.
- Subjects who qualify for the study while taking an SSRI must have been taking their current dose or a higher dose for at least 12 weeks prior to study baseline.
- Subjects who qualify for the study while taking fluvoxamine must be taking no more than 150 mg/day and never had a trial at a higher dose, must be believed by the investigator to be able to tolerate an increase to 250 mg/day starting at baseline, and must have been taking their pre-study dose or a higher dose (up to 150 mg/day) for at least 12 weeks prior to study baseline.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00743834
Contacts
| Contact: Amy Perkins, BA | 414-328-3702 | aperkins@rogershospital.org |
Locations
| United States, Wisconsin | |
| The Rogers Center for Research & Training, Inc. | Not yet recruiting |
| Milwaukee, Wisconsin, United States, 53227-1133 | |
| Contact: Amy Perkins, BA 414-328-3702 aperkins@rogershospital.org | |
| Contact: Alex Bruss, BS 414-328-3710 abruss@rogershospital.org | |
| Principal Investigator: John H Greist, MD | |
Sponsors and Collaborators
Rogers Center for Research & Training, Inc.
Investigators
| Principal Investigator: | John H Greist, MD | The Rogers Center for Research & Training, Inc. |
More Information
No publications provided
| Responsible Party: | John H Greist, MD, Rogers Center for Research & Training, Inc. |
| ClinicalTrials.gov Identifier: | NCT00743834 History of Changes |
| Other Study ID Numbers: | JIIT-07-LCR001a |
| Study First Received: | August 28, 2008 |
| Last Updated: | September 3, 2008 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Obsessive-Compulsive Disorder Compulsive Personality Disorder Anxiety Disorders Mental Disorders Personality Disorders Fluvoxamine Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
Serotonin Agents Physiological Effects of Drugs Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants |
ClinicalTrials.gov processed this record on June 18, 2013